Caption Management LLC Makes New $525,000 Investment in Bioventus Inc. (NYSE:BVS)

Caption Management LLC acquired a new stake in Bioventus Inc. (NYSE:BVS - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 50,000 shares of the company's stock, valued at approximately $525,000. Caption Management LLC owned about 0.06% of Bioventus at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in BVS. Tower Research Capital LLC TRC grew its holdings in Bioventus by 106.1% during the fourth quarter. Tower Research Capital LLC TRC now owns 3,469 shares of the company's stock worth $36,000 after acquiring an additional 1,786 shares during the period. Plato Investment Management Ltd acquired a new stake in shares of Bioventus during the fourth quarter valued at $38,000. KLP Kapitalforvaltning AS acquired a new stake in shares of Bioventus during the fourth quarter valued at $75,000. Quantbot Technologies LP acquired a new stake in shares of Bioventus during the fourth quarter valued at $103,000. Finally, Arizona State Retirement System acquired a new stake in Bioventus in the 4th quarter worth about $109,000. Hedge funds and other institutional investors own 62.94% of the company's stock.

Bioventus Stock Up 2.2%

Shares of NYSE:BVS traded up $0.15 on Monday, reaching $6.83. The company had a trading volume of 111,318 shares, compared to its average volume of 451,150. The company has a quick ratio of 0.99, a current ratio of 1.41 and a debt-to-equity ratio of 1.85. The stock has a 50-day moving average price of $8.40 and a 200 day moving average price of $10.05. The stock has a market capitalization of $559.68 million, a P/E ratio of -11.20 and a beta of 0.95. Bioventus Inc. has a twelve month low of $5.27 and a twelve month high of $14.38.

Analyst Ratings Changes

BVS has been the subject of several research reports. Canaccord Genuity Group reiterated a "buy" rating and set a $15.00 price objective on shares of Bioventus in a research note on Monday, March 17th. Craig Hallum set a $15.00 price objective on Bioventus and gave the company a "buy" rating in a research note on Wednesday.

Insider Buying and Selling

In other news, SVP Anthony D'adamio sold 4,380 shares of the stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $10.19, for a total transaction of $44,632.20. Following the completion of the transaction, the senior vice president now directly owns 118,178 shares in the company, valued at $1,204,233.82. This represents a 3.57% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Mark Leonard Singleton sold 6,498 shares of the firm's stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $10.19, for a total transaction of $66,214.62. Following the completion of the sale, the chief financial officer now owns 118,817 shares of the company's stock, valued at $1,210,745.23. This trade represents a 5.19% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 24,208 shares of company stock worth $226,138 in the last three months. Insiders own 32.90% of the company's stock.

Bioventus Company Profile

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.